Literature DB >> 8898653

Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7.

P E Hesterberg1, D Winsor-Hines, M J Briskin, D Soler-Ferran, C Merrill, C R Mackay, W Newman, D J Ringler.   

Abstract

BACKGROUND & AIMS: Integrins play diverse roles in cellular actions and signalling in the immune system. In the context of mucosal immune responses, the integrin alpha 4 beta 7 has received particular attention because of its intimate involvement in lymphocyte recruitment to normal gastrointestinal mucosa and associated lymphoid tissue. The aim of this study was to determine the functional relevance of alpha 4 beta 7 in the pathogenesis of colonic inflammatory disease using the colitic cotton-top tamarin, an animal model of human ulcerative colitis.
METHODS: Chronically colitic cotton-top tamarins were given either a cross-reactive monoclonal antibody to human alpha 4 beta 7 or an irrelevant control monoclonal antibody. The animals were then evaluated clinically and mucosal biopsy specimens assessed by histological and quantitative morphometric analysis.
RESULTS: A blocking monoclonal antibody to alpha 4 beta 7 integrin ameliorated inflammatory activity and rapidly improved stool consistency when administered to chronically colitic animals. Furthermore, using morphometric analysis of biopsy specimens, antibody therapy reduced the mucosal density of alpha 4 beta 7+ lymphocytes and alpha 4 beta 7 neutrophils and macrophages.
CONCLUSIONS: These results suggest that the alpha 4 beta 7 integrin represents a novel, potentially organ-specific therapeutic target for the treatment of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898653     DOI: 10.1053/gast.1996.v111.pm8898653

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  72 in total

Review 1.  Molecules controlling lymphocyte migration to the gut.

Authors:  M Salmi; S Jalkanen
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

Review 2.  Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?

Authors:  Tim Raine
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

3.  Quantitative and functional characteristics of intestinal-homing memory T cells: analysis of Crohn's disease patients and healthy controls.

Authors:  A L Hart; M A Kamm; S C Knight; A J Stagg
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

Review 4.  Alpha 4 integrin blockade in inflammatory bowel disease.

Authors:  S Ghosh
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

5.  Osteopontin biomarker in inflammatory bowel disease, animal models and target for drug discovery.

Authors:  Manuela G Neuman
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

Review 6.  Review of vedolizumab for the treatment of ulcerative colitis.

Authors:  Michelle Sy Lau; Her Hsin Tsai
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

7.  Impaired mitogenic response of peripheral blood T cells in ulcerative colitis is not due to apoptosis.

Authors:  M A Pérez-Machado; L M Espinosa; E J de la Madrigal; L Abreu; G M Lorente; M Alvarez-Mon
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

8.  Anti-adhesion molecule therapy for inflammatory bowel disease.

Authors:  Subrata Ghosh; Remo Panaccione
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

9.  Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells.

Authors:  Bertus Eksteen; J Rodrigo Mora; Emma L Haughton; Neil C Henderson; Laura Lee-Turner; Eduardo J Villablanca; Stuart M Curbishley; Alex I Aspinall; Ulrich H von Andrian; David H Adams
Journal:  Gastroenterology       Date:  2009-02-21       Impact factor: 22.682

10.  Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis.

Authors:  Christina Ha; Asher Kornbluth
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.